India Pharma Outlook Team | Wednesday, 27 April 2022
Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global pharmaceutical company, received the “India Pharma Innovation of the Year” Award and was adjudged runners-up in the “India Pharma CSR of the Year” category, as part of the India Pharma & India Medical Device Awards 2022.
The seventh edition of the annual awards was jointly organized by the Department of Pharmaceuticals, ministry of chemicals & fertilizers, the Federation of Indian Chambers of Commerce & Industry (FICCI) and Invest India.
The award recognizes Glenmark’s multiple patents and innovations in its core therapy areas of dermatology, respiratory and oncology, over the last three years. It also acknowledges the Company’s contribution to the healthcare sector, in meeting both pressing and long-term patient needs.
Commenting on this prestigious honor, Glenn Saldanha, chairman and managing director of Glenmark Pharmaceuticals, said “Our focus has always been on the holistic development of innovative medicines for India and the world. We are proud to receive the award which reaffirms our commitment to introducing novel drugs for unmet medical needs.
The recognition through these awards will provide further impetus to research and development in the Indian pharmaceutical sector.” Glenmark has previously won awards from the Department of Pharmaceuticals under the categories of India Pharma Leader Award (2015), Company of the Year (2016), Corporate Social Responsibility Programme of the Year (2017) and ‘Indian Pharma Innovation of the Year’ (2021).